Growth response to growth hormone-releasing hormone(1-29)-NH2 compared with growth hormone

What Was Tested

This randomized controlled trial paper looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRH (Growth Hormone-Releasing Hormone).

Evaluation included anthropometry, bone age, intravenous and subcutaneous GHRH(1-29)-NH2 tests and determination of insulin-like growth factor I (IGF-I) levels.

Height velocity during treatment was lowest in the LD group, but comparable in the HD and GH groups.

Who Took Part

The abstract describes 43 children taking part.

The age groups tagged for this paper are young children, children and teenagers, both men and women.

All children were treated for a period of 6 months.

How the Study Was Run

The design is described as randomized.

Random assignment meant chance, not the researchers, decided who got Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and who got the comparison, which limits bias.

The methods mention a period of 6 months.

What Was Measured

Evaluation included anthropometry, bone age, intravenous and subcutaneous GHRH(1-29)-NH2 tests and determination of insulin-like growth factor I (IGF-I) levels.

Topics PubMed links to this paper include Age Determination by Skeleton, Anthropometry, Body Height, Growth Disorders, Growth Hormone, Insulin-Like Growth Factor I and Sermorelin.

What This Means in Plain Language

The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRH (Growth Hormone-Releasing Hormone) in 43 children over 6 months.

The publication is from 1993 (Acta paediatrica (Oslo, Norway : 1992). Supplement), a journal based in Norway.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page and the GHRH (Growth Hormone-Releasing Hormone) compound page, all human trials.